Close menu

January 18th, 2024 | 08:30 CET

Morphosys on the verge of a short squeeze? Evotec share drops like a stone! Almonty Industries is exciting!

  • Mining
  • Tungsten
  • Biotechnology
  • Pharma
Photo credits: BMW Group

Share price disaster at Evotec. The shares of the German biotech company are falling like a stone in 2024 and have already lost over 30% of their value in just a few trading days. This results from the CEO's surprising resignation and delayed reports of insider transactions. "Manager-Magazin" added fuel to the fire with an article. Morphosys, on the other hand, is taking off. The blood cancer drug Pelabresib is causing speculation and price swings. Could there even be a short squeeze? The Almonty Industries share is also exciting at the moment. The shares of the raw materials company, which focuses on tungsten, appear to have bottomed out and are starting an upward trend. Operationally, Almonty is facing exciting times. Analysts expect the tungsten producer to more than triple its turnover between 2023 and 2025. Given the expected profit in the coming year, the share is anything but expensive.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: MORPHOSYS AG O.N. | DE0006632003 , EVOTEC SE INH O.N. | DE0005664809 , ALMONTY INDUSTRIES INC. | CA0203981034

Table of contents:

    Almonty Industries: Investors recognize opportunity

    We had already pointed out in December that the stock of Almonty Industries could see a breakthrough in 2024. And the start of the year has been successful. In a relatively weak environment overall, the tungsten producer's shares have already gained over 10% this year and are trading at CAD 0.62. The Canadian raw materials company with activities in Spain, Portugal and South Korea thus appears to have bottomed out and is now on an upward trend. There is a resistance zone between CAD 0.60 and CAD 0.67. If the breakout succeeds, it will be really exciting, as the share was already at CAD 0.86 at the beginning of 2023 and above CAD 1 in 2022. The analysts at the German Sphene Capital believe that the Almonty Industries share price could even reach CAD 1.69.

    The rise in stock price indicates that the Almonty story is gaining momentum. The tungsten producer is likely facing a pivotal year. In 2023, the Los Santos Mine in Spain underwent maintenance and was back in operation by the end of the year. Sphene analysts believe the mine will generate annual sales of over CAD 20 million. Almonty is currently working on expanding the Panasqueira mine in Portugal, aiming to double the annual tungsten oxide production of the Company's current cash cow and extend its service life. And then, of course, there is the Sangdong project. The mine in South Korea is to be commissioned this year, potentially becoming a game changer and positioning Almonty as a leading global producer of the critical metal tungsten. The development is co-financed by the German KfW. Of the committed loan volume of USD 75.1 million, USD 53.9 million has already been disbursed in several tranches. Thanks to these three cornerstones, analysts at Sphene Capital expect Almonty to be able to increase its turnover and profits to a new league. Sales are expected to more than triple from CAD 28.9 million last year to around CAD 100 million by 2025. In the coming year, Almonty should then be able to generate an after-tax profit of CAD 24.5 million - and the trend will continue upwards. At the current share price, the Company is valued at around CAD 145 million, suggesting that the share may have further room for growth.

    Evotec facing share price disaster

    Investors are currently abandoning Evotec shares. The milestone payment of USD 25 million by partner Bristol Myers Squibb is being overlooked. Instead, the surprising resignation of the long-standing CEO Werner Lanthaler, in conjunction with insider transactions published very late, is shaking investors' confidence. Numerous purchases and sales by Lanthaler from 2022 were only reported this year, raising concerns as such disclosures are typically expected within a few days. The "Manager-Magazin" adds fuel to the fire with an article titled "How the Evotec CEO Concealed Million-Dollar Deals for Years". According to the article, Lanthaler sold Evotec shares worth EUR 6 million before the partial exit of major shareholder Oetker became known and put the share under pressure. And according to the "Manager-Magazin," this is not the end of the story.

    The day before yesterday, the T. Rowe Price International Stock Fund announced that its stake in Evotec had fallen below the 5% threshold. Although the volume sold is limited, it could indicate that more prominent investors are also having doubts about the Company.

    The analysts at RBC also see reputational damage. Evotec itself may have published the insider transactions in good time but only received them from Lanthaler far too late. The analysts maintain their neutral assessment even after the share price slid from over EUR 21 to below EUR 14. For them, Evotec is a "Sector Perform" with a target price of EUR 18.60.

    Morphosys: Share on the verge of a short squeeze?

    Morphosys shares are at their highest level since the end of 2021. On Tuesday alone, it shot up by over 12% to EUR 38. That means the stock has more than doubled since the end of November 2023. However, there are also repeated double-digit price setbacks. Study data on the blood cancer drug pelabresib in November still seems to be fueling speculation. Is this speculation positive or negative? Even Morgan Stanley appears to be in two minds. Although the analysts see a sales potential of over USD 1 billion, they downgraded the share from "Overweight" to "Equal Weight". Short sellers are likely also contributing to the price fluctuations. The biotech company is popular among short sellers. If Morphosys shares continue to show relative strength or there is even positive news on pelabresib, a short squeeze is likely.

    The Morphosys share is traditionally not for the faint-hearted. The pipeline is manageable, and thus, the price swings caused by individual reports are high. Its popularity among short sellers is a constant source of excitement. This year will be exciting for Almonty. If the measures discussed for the three mines are implemented as presented and sales and earnings growth is initiated, significantly higher share prices are possible. Although Evotec could see a recovery rally at any time, the loss of confidence should not be underestimated, even if the Company itself is not to blame.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by André Will-Laudien on June 17th, 2024 | 06:45 CEST

    Acute threat? Armaments and high-tech in the crosshairs: Aixtron, Almonty Industries, Rheinmetall and Hensoldt

    • Mining
    • Tungsten
    • hightech
    • Defense
    • armaments

    The recent European elections have enabled the conservative camp to make significant gains. Undoubtedly, a whole bouquet of issues has led to the so-called "shift to the right". In times of war, however, the neutral observer may not be surprised that the self-proclaimed peace parties, represented by the colours red and green, have lost considerable ground. After all, the competence for peacemaking and security in Europe tends to be found in the conservative camp. The capital markets currently favour high-tech and armaments, orders are booming, and growth is assured for years to come. It is now crucial for stock market players to take a closer look at these sectors, as the high-yield performers of the first half of the year appear to be correcting more strongly. What will happen here in the medium term?


    Commented by Armin Schulz on June 17th, 2024 | 06:30 CEST

    BioNTech, dynaCERT, Plug Power - A single piece of news can change everything

    • Hydrogen
    • greenhydrogen
    • Biotechnology

    Share prices are characterized by their high volatility and can undergo significant changes in a short space of time. Often, just one piece of company news can completely change investor confidence. Shares that were previously under selling pressure and were avoided can suddenly become very popular and experience considerable price increases. Examples include Lufthansa, whose share price rose significantly with the end of the COVID-19 pandemic. Market sentiment can turn quickly when negative factors disappear. A single piece of positive company news can prompt investors to become more involved again, significantly increasing demand and, consequently, the share price. We have identified three potential turnaround candidates.


    Commented by Fabian Lorenz on June 13th, 2024 | 07:00 CEST

    Stocks on the verge of a breakout! Rheinmetall, TUI, Desert Gold

    • Mining
    • Gold
    • Defense
    • Travel

    Will Rheinmetall soon reach a new all-time high? An insider thinks so and is buying a sizeable block of shares in the armaments group. The news situation could hardly be better for the DAX-listed company. The price of gold could also break out and rise to USD 2,700 in the next wave, according to a renowned expert. Desert Gold should benefit noticeably from this. The Company's market capitalization is only a fraction of the proven gold resource, and drilling continues. And what is TUI doing? The share is not making any real progress. However, it should benefit from the FTI collapse, and the crucial summer season brings a high booking volume.